Acciones Isodiol International Inc. Canadian Securities Exchange
Acciones
ISOL
CA46500L2003
Farmacéuticos
Ventas 2018 | 19,14 M 26,11 M 17,82 M | Ventas 2019 | 22,25 M 30,36 M 20,71 M | Capitalización | 49,96 M 68,17 M 46,51 M |
---|---|---|---|---|---|
Resultado Neto 2018 | -36 M -49,12 M -33,52 M | Resultado Neto 2019 | -126 M -172 M -117 M | VE / Ventas 2018 | 12,6 x |
Posición de caja neta 2018 | 15,55 M 21,22 M 14,48 M | Deuda neta 2019 | 5,22 M 7,13 M 4,86 M | VE / Ventas 2019 | 2,48 x |
P/E ratio 2018 |
-4,94
x | P/E ratio 2019 |
-0,37
x | Empleados | - |
Rendimiento 2018 * |
-
| Rendimiento 2019 |
-
| Flotante | 100 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/05/17 |
Director/Board Member | - | 30/08/18 | |
Kevin Swadish
PRN | Corporate Officer/Principal | - | 14/02/19 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/05/17 |
Director/Board Member | - | 30/08/18 | |
Director/Board Member | - | 21/11/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+29,76 % | 5677,95 M | |
-32,34 % | 3592,89 M | |
0,00 % | 3121,15 M | |
-25,09 % | 2624,14 M | |
-10,35 % | 2301,56 M | |
+41,50 % | 1880,89 M | |
+40,90 % | 1451,34 M | |
-15,16 % | 1393,6 M | |
+42,86 % | 1372,45 M |